Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
23.96
-0.93 (-3.74%)
Jul 20, 2026, 4:00 PM EDT - Market closed
Aktis Oncology Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Aktis Oncology stock has a consensus rating of "Strong Buy" and an average price target of $34.38. The average 1-year stock price forecast is 43.49% higher than the current stock price, while the lowest is $31.25 (+30.43%) and the highest is $40 (+66.94%).
Price Target: $34.38 (+43.49%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Aktis Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 5 | 5 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Reiterates $30 → $33 | Buy | Reiterates | $30 → $33 | +37.73% | Jul 14, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 14, 2026 |
| Raymond James | Raymond James | Buy Initiates $40 | Buy | Initiates | $40 | +66.94% | Jun 15, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $35 | Buy | Reiterates | $35 | +46.08% | Jun 2, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $34 | Buy | Maintains | $34 | +41.90% | Jun 1, 2026 |
Financial Forecast
Revenue This Year
10.70M
from 6.50M
Increased by 64.64%
Revenue Next Year
11.55M
from 10.70M
Increased by 7.98%
EPS This Year
-1.62
from -78.34
EPS Next Year
-1.97
from -1.62
EPS and Forward PE are based on non-GAAP adjusted numbers.